News & Updates

Patient delay appears to be as troublesome as system delay when it comes to the incidence of in-hospital deaths among patients with ST-segment elevation myocardial infarction (STEMI) who are undergoing primary percutaneous coronary intervention (PCI), reveals a study.

Findings from the RSQ-777-02 trial demonstrate the ability of a novel intranasal formulation of bumetanide, a standard loop diuretic, to reduce tissue swelling caused by heart failure (HF) as effectively as conventional oral and IV formulations.